Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
Dr Richard Jeremy Gralla speaks to ecancer at the SLAGO 2019 meeting in Chile about his presentations of supportive cancer care.
Dr Gralla provides these perspectives with a focus on GI malignancies, talking about prevention of nausea and vomiting.
He then outlines some of the differences and similarities between cancer care in America and Latin America.
Dr Gralla finalises by emphasising the importance of collaboration through communication and learning.
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
Latest treatments in oesophageal cancer
Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC
Neo-adjuvant therapy for different cancers in the Philippines